Abstract Novel interventions for post-traumatic stress disorder (PTSD) leverage the psychoactive properties of psychedelic compounds, such as ketamine, 3,4-methylenedioxymethamphetamine and…
Abstract Introduction: PolDrugs is a biennial epidemiological study aimed at analyzing patterns of mostly illicit psychoactive substance use in Poland…
Abstract Background: The substitution of cannabis for alcohol and other drugs has been conceptualised in a harm reduction framework as…
Abstract 3,4-Methylenedioxymethamphetamine (MDMA) is being investigated in controlled clinical trials for use as an adjunct medication treatment for post-traumatic stress…
Abstract Objective: This study aims to provide an overview of pharmacological trials that examine the neurocognitive effects of psychedelics among…
Abstract Introduction: Cannabis use disorder (CUD) is prevalent in ~2–5% of adults in the United States and is anticipated to…
Abstract 3,4-Methylenedioxymethamphetamine (MDMA) is currently being investigated as an adjunctive treatment to therapy for posttraumatic stress and other anxiety related…
Abstract Post-traumatic stress disorder (PTSD) is a chronic psychiatric disease resulting from the experience or witnessing of traumatic events. Persistent…
Abstract Post-traumatic stress disorder (PTSD) is a significant public health concern for which existing therapies are only marginally effective. Indisputably,…
Abstract Although early therapeutic research on psychedelics dates back to the 1940s, this field of investigation was met with many…